Condition: Non-Small Cell Lung Cancer · Sponsor: Bristol-Myers Squibb
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building | Irvine, California, United States | Recruiting |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange, California, United States | Recruiting |
| Shaw Cancer Center | Edwards, Colorado, United States | Recruiting |
| Local Institution - 0085 | Gainesville, Florida, United States | Withdrawn |
| Local Institution - 0142 | Pembroke Pines, Florida, United States | Not Yet Recruiting |
| Piedmont Healthcare | Atlanta, Georgia, United States | Recruiting |
| John B Amos Cancer Center | Columbus, Georgia, United States | Recruiting |
| Rush University Medical Center | Chicago, Illinois, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Renown Regional Medical Center | Reno, Nevada, United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island | Mineola, New York, United States | Recruiting |
+ 174 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07100080